Literature DB >> 3493064

Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.

S Harkonen, J Stoudemire, R Mischak, L E Spitler, H Lopez, P Scannon.   

Abstract

This study was performed to assess the subacute toxicity and immunogenicity in rats of XOMAZYME-MEL, an antimelanoma monoclonal antibody-ricin A chain immunotoxin. Female Sprague-Dawley rats received 14 consecutive daily i.v. injections of XOMAZYME-MEL at doses of 5 mg/kg/day, 1 mg/kg/day, or normal saline. Animals from each dose group were sacrificed on days 8, 15, and 22. The low dose of immunotoxin was well tolerated and produced only minimal signs of toxicity. Side effects in animals receiving the high dose of immunotoxin consisted of transient weight loss, peripheral edema, leukocytosis, hypoalbuminemia, and mildly elevated liver function tests. Histological findings in these animals included cytoplasmic vacuolization of hepatocytes, focal myocardial and skeletal muscle degeneration, and renal deposits of proteinaceous casts. The administration of immunotoxin resulted in the appearance of anti-mouse and antiricin A chain immunoglobulin binding activity in the sera of treated animals. This study documents the systemic effect of the multiple-dose administration of a ricin A chain immunotoxin in rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493064

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.

Authors:  A A Hertler; D M Schlossman; M J Borowitz; D G Poplack; A E Frankel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Cultured cell lines from human breast cancer biopsies and xenografts.

Authors:  W M Lewko; R Vaghmar; D Hubbard; M Moore; Y J He; L Chang; S Husseini; K Wallwork; G B Thurman; R K Oldham
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

Review 3.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

Authors:  M Tommasi; D Castelletti; M Pasti; G Fracasso; I Lorenzetti; S Sartoris; C Pera; G B Ferrara; G Tridente; M Colombatti
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

Review 5.  Preparation of recombinant RNase single-chain antibody fusion proteins.

Authors:  Dianne L Newton; Susanna M Rybak
Journal:  Mol Biotechnol       Date:  2002-01       Impact factor: 2.695

Review 6.  Rational immunotherapy with ribonuclease chimeras. An approach toward humanizing immunotoxins.

Authors:  S M Rybak; H R Hoogenboom; D L Newton; J C Raus; R J Youle
Journal:  Cell Biophys       Date:  1992 Aug-Dec

7.  Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects.

Authors:  T Kikuchi; T Ohnuma; J F Holland; L E Spitler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  A rat model for imaging the effect of anti mouse antibody responses on the biodistribution of radiolabelled mouse monoclonal antibodies.

Authors:  M V Pimm; A C Perkins; L G Durrant; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1988

9.  Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.

Authors:  P Brusa; F Pietribiasi; G Bussolati; F Dosio; R Arione; P M Comoglio; M Prat; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 10.  The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations.

Authors:  Aleksander Rust; Lynda J Partridge; Bazbek Davletov; Guillaume M Hautbergue
Journal:  Toxins (Basel)       Date:  2017-10-27       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.